PBAC's latest decision on Memantine hydrochloride: Recommended with restriction (2008). Considered for Treatment of moderately severe Alzheimer's disease in patients with baseline (Standardised) Mini-Mental State Examination ((S)MMSE) score of 10-14.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2007
Submissions
2
2007 → 2008
Eligible population
Adults with moderately severe Alzheimer's disease with baseline (Standardised) Mini-Mental State Examination ((S)MMSE) score of 10-14
Therapy area
Neurology
Line of therapy
Any
Evidence base
Meta-analysis
Primary endpoint
Cognitive and functional outcomes (MMSE, ADAS-COG, activities of daily living)
Key trials
MEM-MD-01, MEM-MD-10, MRZ-9605, 99679
Comparator
donepezil, galantamine, rivastigmine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis based on indirect meta-analysis; no ICER presented
Submission history
Mar 2007: Not recommended
Mar 2008: Recommended with restriction · Authority Required